The process of registering medicines with the National Health Surveillance Agency (ANVISA) is one of the fundamental pillars for guaranteeing the safety, efficacy and quality of pharmaceutical products marketed in Brazil. Companies wishing to launch new drugs on the domestic market must thoroughly understand each regulatory stage, its legal, technical and scientific requirements. In this blog, we'll cover the main topics on drug registration with ANVISA. Read on!
TALK TO AN EXPERT
What you'll see in this blog:
The registration of medicines is a legal and technical public act, carried out by ANVISA, which authorizes the marketing of a medicine in the national territory. This registration certifies that the product meets all the quality, safety and efficacy criteria established by Brazilian legislation. The registration requirement establishes the specific procedures and requirements for registering new, generic, similar and specific medicines, among others. Without registration, a medicine cannot be legally produced or marketed in Brazil. In addition, registration is valid for 10 years and can be renewed upon proof that the product continues to meet current regulatory requirements.
ANVISA classifies medicines into several categories, each of which has different requirements for the registration process. The main categories are
A correct understanding of the category of medicine is crucial, as it has a direct impact on the documentation required and the regulatory strategy adopted.
ANVISA has made efforts to reduce the time it takes to analyze drug registrations, mainly through programs that speed up the process for priority drugs. However, the average time for registration can vary from 12 to 24 months, depending on the category and the quality of the documentation submitted.
At Stone Okamont, we understand that each regulatory project is unique and requires a personalized approach. Our team of experts acts with excellence and precision at every stage of the process, from the classification of the drug to the submission of the dossier, including liaison with ANVISA and post-registration support. If you want to register a drug in Brazil safely and quickly, rely on those with proven experience in the regulatory market. Contact Stone Okamont.
Request a quote here.